Beijing Foyou Pharma (601089.SH): Rotigotine Patch Receives Drug Registration Certificate

Beijing Foyou Pharma (601089.SH) announced that it recently received the Drug Registration Certificate (Certificate No. 2026S03864) issued by the National Medical Products Administration for Rotigotine Patches (specifications: 2mg/24 hours, 4.5mg/patch), approving the production of the drug. The Rotigotine Patch, developed by UCB, was first approved in the EU through the centralized review procedure in February 2006. In June 2018, it was approved by the National Medical Products Administration for marketing in China. The drug is indicated for monotherapy (not in combination with levodopa) in early-stage idiopathic Parkinson's disease to treat symptoms and signs, or in combination with levodopa throughout the course of the disease, until the late stages when levodopa efficacy declines, becomes unstable, or fluctuates (end-of-dose phenomenon or "on-off" phenomenon).